Sageworth Trust Co Takes Position in Mesoblast Limited (NASDAQ:MESO)

Sageworth Trust Co acquired a new position in shares of Mesoblast Limited (NASDAQ:MESO) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 10,000 shares of the company’s stock, valued at approximately $198,000.

A number of other institutional investors have also made changes to their positions in the stock. R Squared Ltd bought a new position in Mesoblast during the fourth quarter worth about $30,000. Signaturefd LLC boosted its stake in Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after acquiring an additional 3,099 shares during the last quarter. GAMMA Investing LLC grew its holdings in Mesoblast by 22.1% during the fourth quarter. GAMMA Investing LLC now owns 6,711 shares of the company’s stock valued at $133,000 after purchasing an additional 1,213 shares during the period. China Universal Asset Management Co. Ltd. bought a new stake in Mesoblast in the fourth quarter valued at approximately $134,000. Finally, Creative Planning acquired a new stake in Mesoblast in the third quarter worth $147,000. 1.43% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MESO has been the subject of several research analyst reports. Jefferies Financial Group lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a report on Monday, December 23rd. Cantor Fitzgerald raised Mesoblast to a “strong-buy” rating in a research note on Thursday, January 30th. Finally, Piper Sandler restated an “overweight” rating and issued a $24.00 price target (up from $15.00) on shares of Mesoblast in a report on Friday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Mesoblast Trading Up 4.3 %

Shares of MESO stock opened at $19.49 on Friday. Mesoblast Limited has a 12-month low of $1.75 and a 12-month high of $22.00. The firm has a fifty day moving average of $16.33 and a 200-day moving average of $10.92. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18.

Mesoblast Company Profile

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.